Sigma Tau to Conduct Phase II Clinical
Selected Abstract
Sigma-Tau to Conduct Phase II Clinical Trial in Europe with TB4 for Venous Stasis Ulcers; Pharmaceutical Firm Accelerates Phase II Commitment.
BETHESDA, Md. -- RegeneRx Biopharmaceuticals, Inc. (OTCBB:RGRX) (www.regenerx.com) announced today that its strategic partner, Sigma-Tau Group (Sigma-Tau), is planning to conduct a Phase II clinical trial in Europe in the 4th quarter of 2004 to test Thymosin beta 4 (TB4) for the treatment of ... June 23, 2004; Business Wire
Read the full article with a free-trial membership at HighBeam Research
Related Articles 1.
Sigma-Tau to Conduct Phase II Clinical Trial in Europe with TB4 for Venous Stasis Ulcers; Pharmaceutical Firm Accelerates Phase II Commitment.
|
